In the present study we demonstrated for the first time the synergistic antitumor effect between a HDACi, such as vorinostat or VPA, and the anti-ErbB3 MoAb A3, in a set of NSCLC primary tumor cultures. This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.